Changhoon Yoo, MD, PhD, Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the use of circulating tumor DNA (ctDNA) in oncology. The use of ctDNA analysis has been extensively studied in rectal cancer and is now being explored in other cancer types, including biliary tract cancer. In this trial, precision medicine, utilizing ctDNA analysis, shows promise for improving clinical outcomes in the early stages of cancer. This represents a significant step forward in the field of precision medicine, aiming to achieve better outcomes for patients with early-stage cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.